Navigation Links
Preclinical Update - Debio-0512 Therapeutic Vaccine for the,Treatment of Chronic and Acute Inflammatory Conditions

Proof of Concept in Mice Transgenic for Human TNFa

LAUSANNE, Switzerland, March 12, 2007 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development company specialising in oncology and serious medical conditions, announces the presentation of preclinical results that validate the mechanism of action of Debio-0512 as an anti-TNFa therapeutic vaccine, that inhibits inflammatory processes in animal models of acute and chronic inflammation. Debio-0512 is a keyhole limpet hemocyanin (KLH)-human TNFa heterocomplex (hTNFa kinoid). The results of this study, published recently in the Proceedings of the National Academy of Sciences (PNAS), were presented on March 10 at the 4th International Conference on Tumor Microenvironment in Florence, Italy.

"These results confirm that therapeutic vaccination against human TNFa could represent in the future, an effective approach for the treatment of TNFa-dependent inflammatory pathologies including rheumatoid arthritis and Crohn's disease," said Professor Daniel Zagury of the University Pierre et Marie Curie (Paris) and co-author of the report. "Debiopharm's plan is for IND enabling clinical studies to be ready by the end of this year. We believe that active immunization may offer advantages over passive anti-TNFa monoclonal antibody therapy, by potentially limiting therapeutic failure related to the formation of anti-idiotypic antibodies. Moreover, the potential low frequency of boost immunizations would increase patient compliance."

TNFa is a well-established pro-inflammatory mediator. In hTNFa expressing transgenic mice (TTg mice), a mouse model of rheumatoid arthritis, animals receiving the Debio-0512 therapeutic vaccine developed high levels of anti-TNFa antibodies, neutralising both TNFa bioactivity and binding of TNFa to its receptor. This study shows that immunization with Debio-0512 effectively controls pathogenic effec ts triggered by TNFa in this mouse model of rheumatoid arthritis.

About Debiopharm Group

Debiopharm Group is a global biopharmaceutical development company that in-licenses promising biologics and small molecule drug candidates. Debiopharm develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed three products with global combined sales in excess of $2.6 billion in 2006.

For more information on Debiopharm Group, please visit: www.debiopharm.com.

CONTACT: Debiopharm S.A. Contacts: Herve Porchet, VP, Medical Affairs,Tel.: +41-21-321-01-11, Fax: +41-21-321-01-69, . KimBill, VP, Business & Legal Affairs, . Additional MediaContacts: In London: Maitland, Brian Hudspith, Tel: +44-(0)20-7379-5151,. In New York: Noonan Russo, Wendy Lau, Tel:+1-212-845-4272, Fax: +1-212-845-4260, hporchet@debio.com kbill@debio.com bhudspith@maitland.co.uk wendy.lau1@eurorscg.com

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
3. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
4. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
7. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
8. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
9. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
10. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
11. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Global Blood Therapeutics, ... company developing novel therapeutics for the treatment of ... announced the closing of its previously announced underwritten ... at the public offering price of $18.75 per ... were offered by GBT. GBT estimates net proceeds ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... announced today its affiliation with Tennessee Counseling Association. This new relationship ... of the Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA ...
(Date:6/26/2016)... N.J. (PRWEB) , ... June 27, 2016 , ... Quality ... sources, yet in many ways they remain in the eye of the beholder, according ... (EBO), a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... ... ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a weight ... app plans to fix the two major problems leading the fitness industry today:, ... program , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
Breaking Medicine News(10 mins):